Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/thoraxjnl-2015-207170 http://scihub22266oqcxt.onion/10.1136/thoraxjnl-2015-207170 26219978!4717417!26219978     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Thorax 2016 ; 71 (1): 73-83 Nephropedia Template TP {{tp|p=26219978|t=2016. The molecular targets of approved treatments for pulmonary arterial hypertension |pdf=|usr=}}{{26219978}} gab.com Text The molecular targets of approved treatments for pulmonary arterial hypertension JO: Thorax http://www.kidney.de/pget.php?&tw=1&pmid=26219978 #FOAvip Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)--prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an additional drug class has become available targeting a distinct molecular target in the same pathway as PDE5 inhibitors. Treatment recommendations currently include the use of all four drug classes to treat PAH, but there is a lack of comparative data for these therapies. Therefore, an understanding of the mechanistic differences between these agents is critical when making treatment decisions. Combination therapy is often used to treat PAH and it is therefore important that physicians understand how the modes of action of these drugs may interact to work as complementary partners, or potentially with unwanted consequences. Furthermore, different patient phenotypes mean that patients respond differently to treatment; while a certain monotherapy may be adequate for some patients, for others it will be important to consider alternating or combining compounds with different molecular targets. This review describes how the four currently approved drug classes target the complex pathobiology of PAH and will consider the distinct target molecules of each drug class, their modes of action, and review the pivotal clinical trial data supporting their use. It will also discuss the rationale for combining drugs (or not) from the different classes, and review the clinical data from studies on combination therapy. Twit Text FOAVip The molecular targets of approved treatments for pulmonary arterial hypertension ????Thorax http://www.kidney.de/pget.php?&tw=1&pmid=26219978 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26219978 #FOAvip English Wikipedia <ref>{{Cite pmid|26219978}}</ref> The molecular targets of approved treatments for pulmonary arterial hypertension #MMPMID26219978 Humbert M; Ghofrani HA Thorax 2016[Jan]; 71 (1): 73-83 PMID26219978show ga Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)--prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an additional drug class has become available targeting a distinct molecular target in the same pathway as PDE5 inhibitors. Treatment recommendations currently include the use of all four drug classes to treat PAH, but there is a lack of comparative data for these therapies. Therefore, an understanding of the mechanistic differences between these agents is critical when making treatment decisions. Combination therapy is often used to treat PAH and it is therefore important that physicians understand how the modes of action of these drugs may interact to work as complementary partners, or potentially with unwanted consequences. Furthermore, different patient phenotypes mean that patients respond differently to treatment; while a certain monotherapy may be adequate for some patients, for others it will be important to consider alternating or combining compounds with different molecular targets. This review describes how the four currently approved drug classes target the complex pathobiology of PAH and will consider the distinct target molecules of each drug class, their modes of action, and review the pivotal clinical trial data supporting their use. It will also discuss the rationale for combining drugs (or not) from the different classes, and review the clinical data from studies on combination therapy. |Antihypertensive Agents/administration & dosage/*therapeutic use[MESH] |Drug Interactions[MESH] |Drug Therapy, Combination[MESH] |Endothelin Receptor Antagonists/administration & dosage/therapeutic use[MESH] |Humans[MESH] |Hypertension, Pulmonary/*drug therapy[MESH] |Phosphodiesterase Inhibitors/administration & dosage/therapeutic use[MESH] |Prostaglandins/administration & dosage/therapeutic use[MESH] |Pyrazoles/administration & dosage/therapeutic use[MESH]The molecular targets of approved treatments for pulmonary arterial hy(epmc).pdf DeepDyve Pubget Overpricing